MHRA Clinical Trial Update: A New Era for UK Research

Today marks a pivotal moment for UK life sciences as the MHRA introduces the most significant update to clinical trial regulations in two decades. This update represents a strategic shift towards a more agile, transparent, and future-ready research environment.

The new framework is expected to streamline processes, reduce unnecessary complexity, and improve the overall efficiency of trial management. At the same time, it reinforces the importance of robust governance, clear documentation, and reliable long-term data retention practices. In other words, while the regulatory landscape is becoming more modern and flexible, the expectations around accountability remain as strong as ever.

At Arkivum, we welcome these changes as a major step forward for UK clinical trials. By focusing on transparency, efficiency, and data integrity, the MHRA is helping to create an environment where groundbreaking research can move forward with greater confidence. These updates not only strengthen compliance expectations, but also enhance the UK’s ability to remain competitive on the global stage.

To support teams navigating this transition, Arkivum has published a new eBook, Complying with the New UK Clinical Trial Regulations on Data Retention. The guide explores what the changes mean in practice and offers practical insight into how organisations can adapt their data retention strategies to meet the new requirements.

For a deeper discussion of the update and its wider impact, you can also watch our panel session featuring Sarah Hitching, Sandra Blake, and Matthew Addis, who share expert perspectives on what this regulatory shift means for sponsors an sites.